renal cell carcinoma

腎細胞癌の下大静脈血栓摘除術前に行う定位放射線焼灼療法：新たな第2相エビデンスの総括

Neoadjuvant Stereotactic Ablative Radiotherapy Prior to Inferior Vena Cava Thrombectomy in Renal Cell Carcinoma: A Synthesis of Emerging Phase 2 Evidence

By MedXY 10/20/2026

This review synthesizes phase 2 trial data supporting neoadjuvant stereotactic ablative radiotherapy for RCC with IVC tumor thrombus, highlighting improved recurrence-free survival, acceptable safety, and biomarker insights that underscore its potential as a novel preoperative strategy.

news Oncology

AUC3 2025: Expert Consensus Roadmap for Renal Cell and Urinary Tract Cancer Care

By MedXY 12/19/2025

The 2025 Advanced Urologic Cancer Consensus Conference (AUC3) issues practical, evidence‑informed expert recommendations on diagnosis, perioperative therapy, frontline and later‑line systemic sequencing, and special populations for RCC and urinary tract cancers.

news Oncology Urology

Long-Term Efficacy and Safety of Belzutifan in von Hippel-Lindau Disease-Associated Renal Cell Carcinoma: Insights from the 50-Month LITESPARK-004 Phase 2 Study

By MedXY 10/25/2025

Belzutifan demonstrates sustained tumor response and manageable safety over 50 months in patients with von Hippel-Lindau disease-associated renal cell carcinoma, supporting its role as a systemic therapy.

Nephrology news Oncology

Advancing First-Line Treatment for Advanced Renal Cell Carcinoma: Efficacy of Benmelstobart Plus Anlotinib versus Sunitinib

By MedXY 10/16/2025

This phase 3 trial compares benmelstobart plus anlotinib to sunitinib, demonstrating improved progression-free survival and manageable safety in untreated advanced renal cell carcinoma.

Oncology Pathology & Lab Medicine Specialties

Standardizing Pathological Response Reporting After Neoadjuvant Therapy in Kidney Cancer: New International Guidelines

By MedXY 10/15/2025

International experts issue consensus guidelines for sampling and reporting pathological response to neoadjuvant therapy in renal cell carcinoma, recommending standardized specimen sampling and quantification of residual viable tumor to enable reliable trial endpoints and future clinical use.